Broncus Holding Corp.
HHKEX:22160.55
HKD
-0.01
(-2.65%)
Broncus Holding Corp.
HKEX:2216
(Hong Kong Exchange)
Recent
price
0.55
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
USD
•
in mil. unless spec.Working Capital
USD
•
in mil. unless spec.Growth Rates
USD
•
in mil. unless spec.Semi-annual Revenue
USD
•
in mil. unless spec.Semi-annual Earnings Per Share
USD
•
in mil. unless spec.Semi-annual Dividends Per Share
USD
•
in mil. unless spec.- Similar Companies
- Business
- Broncus Holding Corporation (2216.HK), an investment holding company incorporated in the Cayman Islands in 2012 and headquartered in Hangzhou, Zhejiang Province, People's Republic of China, develops, manufactures and commercializes innovative medical devices and consumables for interventional pulmonology, focusing on diagnostic solutions, lung cancer treatment, chronic obstructive pulmonary disease (COPD) therapies and navigation platforms; core products include the BroncAblate Transbronchial Radiofrequency Ablation System and Disposable Lung Radiofrequency Ablation Catheter for lung cancer ablation via natural orifice, InterVapor for severe COPD and lung cancer via bronchoscopic thermal vapor ablation, Targeted Lung Denervation (TLD) Radiofrequency Ablation System for acute COPD exacerbations, diagnostic tools such as FleXNeedle, ATV Sheath, ATV Balloon and H-Marker, navigation systems including LungPro augmented reality optical whole lung diagnostic and therapeutic navigation (Archimedes outside China), Lungpoint, BroncQCT lung imaging processing software, Mist Fountain disposable nebulizing micro-catheter, BroncTru and general consumables for biopsy, drug delivery and thoracic surgery applications; the company operates principally in Mainland China, the European Union, USA and other regions, serving hospitals and clinicians with one-stop respiratory interventional solutions integrating positioning, navigation, diagnosis and treatment. Recent developments include NMPA approval and commercial launch of BroncAblate in China during the six months ended June 30, 2025 with initial clinical applications in top-tier centers like Shanghai Pulmonary Hospital and West China Medical Center, accumulation of over 500 InterVapor cases across approximately 200 hospitals, ongoing post-marketing trials for InterVapor and pre-marketing enrollment of 109 patients for TLD, Zhejiang approval for BroncQCT in March 2025, promotion of combined navigation-consumables techniques like EBUS-GS-TBLB and EBUS-TTCB, debut of integrated solutions at 2025CMEF Spring, multiple academic presentations including Nanshan Forum, OCTS 2025 and West China Forum pioneering BroncAblate in Southwest China, global showcases at events in Paris, Italy, Amsterdam and domestic conferences, acquisition of 100% equity in Hangzhou Jingliang Medical Technology in November 2023 to enhance R&D for flexible robots and product offerings, partnership fund investment with Venus Medtech (2500.HK) announced in March 2023, historical Series C financing closed in 2020 led by Lake Bleu Capital with Baidu Capital and others, and strategic distribution partnership with Olympus Europa for Archimedes systems in Europe; as of June 30, 2025, the company holds 69 overseas registrations including 4 CE and 7 FDA certificates.